Potential Drug Targets Against Hepatitis B Virus Based on Both Virus and Host Factors
- PMID: 31362671
- DOI: 10.2174/1389450120666190729115646
Potential Drug Targets Against Hepatitis B Virus Based on Both Virus and Host Factors
Abstract
Background: Hepatitis B is a very harmful and epidemic disease caused by hepatitis B virus (HBV). Although an effective anti-HBV vaccine is available, chronic infection poses still a huge health burden in the whole world. The present anti-HBV drugs including nucleoside analogues and interferonalpha have their limitations without exception. There is no effective drug and therapeutic method that can really and truly cure hepatitis B so far. The variability of HBV genome results in that a significant number of patients develop drug resistance during the long-term use of anti-HBV drugs. Hence, it is urgently needed to discover novel targets and develop new drugs against hepatitis B.
Objective: The review aims to provide the theory support for designing of the anti-HBV innovative drugs by offering a summary of the current situation of antiviral potential targets.
Results and conclusion: Since HBV is obligate intracellular parasite, and as such it depends on host cellular components and functions to replicate itself. The targeting both virus and host might be a novel therapeutic option for hepatitis B. Accordingly, we analyse the advances in the study of the potential drug targets for anti-HBV infection, focusing on targeting virus genome, on targeting host cellular functions and on targeting virus-host proteins interactions, respectively. Meanwhile, the immune targets against chronic hepatitis B are also emphasized. In short, the review provides a summary of antiviral therapeutic strategies to target virus factors, host factors and immune factors for future designing of the innovative drug against HBV infection.
Keywords: Hepatitis B virus; drug design; host target; immune target; viral target; virus-host interactions..
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Virological Basis for the Cure of Chronic Hepatitis B.ACS Infect Dis. 2019 May 10;5(5):659-674. doi: 10.1021/acsinfecdis.8b00081. Epub 2018 Jun 25. ACS Infect Dis. 2019. PMID: 29893548 Free PMC article. Review.
-
Latest developments in the treatment of hepatitis B.Minerva Gastroenterol Dietol. 2016 Mar;62(1):88-102. Epub 2015 Oct 8. Minerva Gastroenterol Dietol. 2016. PMID: 26448309 Review.
-
An Effective Antiviral Approach Targeting Hepatitis B Virus with NJK14047, a Novel and Selective Biphenyl Amide p38 Mitogen-Activated Protein Kinase Inhibitor.Antimicrob Agents Chemother. 2017 Jul 25;61(8):e00214-17. doi: 10.1128/AAC.00214-17. Print 2017 Aug. Antimicrob Agents Chemother. 2017. PMID: 28559272 Free PMC article.
-
The current status and future directions of hepatitis B antiviral drug discovery.Expert Opin Drug Discov. 2017 Jan;12(1):5-15. doi: 10.1080/17460441.2017.1255195. Epub 2016 Nov 11. Expert Opin Drug Discov. 2017. PMID: 27797587 Free PMC article. Review.
-
New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus.J Hepatol. 2016 Apr;64(1 Suppl):S117-S131. doi: 10.1016/j.jhep.2016.02.016. J Hepatol. 2016. PMID: 27084032 Review.
Cited by
-
Current Status and Challenges in Anti-Hepatitis B Virus Agents Based on Inactivation/Inhibition or Elimination of Hepatitis B Virus Covalently Closed Circular DNA.Viruses. 2023 Nov 25;15(12):2315. doi: 10.3390/v15122315. Viruses. 2023. PMID: 38140556 Free PMC article. Review.
-
Pharmacological perspectives and molecular mechanisms of coumarin derivatives against virus disease.Genes Dis. 2021 Apr 20;9(1):80-94. doi: 10.1016/j.gendis.2021.03.007. eCollection 2022 Jan. Genes Dis. 2021. PMID: 35005109 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources